8-K: ABVC BioPharma and OncoX BioPharma Partner to Develop Pancreatic Cancer Treatment

ABVC BioPharma and OncoX BioPharma have entered into a licensing agreement to develop and commercialize ABVC's BLEX 404 for pancreatic cancer treatment, with ABVC expecting up to $26.25 million in income and royalties.

Summary

• ABVC BioPharma and its affiliate Rgene Corporation have partnered with OncoX BioPharma to develop and commercialize BLEX 404, a botanical drug extract for pancreatic cancer treatment.
• OncoX will have exclusive rights to develop and commercialize BLEX 404 in 50% of the worldwide markets for 20 years.
• ABVC and Rgene will receive a combined upfront payment of $12.5 million, either in cash or OncoX shares, within 30 days of the agreement.
• An additional $1.25 million milestone payment is due after OncoX's next round of fundraising, though this is not guaranteed.
• ABVC and Rgene are also entitled to 5% royalties on net sales of the licensed product, up to a total of $12.5 million.
• The total potential income for ABVC and Rgene from this agreement is $26.25 million, including the licensing fees and royalties.
• OncoX will be responsible for regulatory filings and commercialization in the licensed territory, while ABVC will provide the product at cost for clinical development.
• The global pancreatic cancer market is projected to reach $7.91 billion by 2032, growing at a CAGR of 13.6% from 2023 to 2032.

Sentiment

Score: 7

Explanation: The document is positive due to the licensing agreement and potential revenue, but there are risks associated with the milestone payment and commercialization.

Positives

• The licensing agreement provides ABVC with a significant upfront payment and potential future royalties.
• The partnership with OncoX leverages their commercialization experience to bring BLEX 404 to market.
• The agreement covers a substantial portion of the global market, increasing the potential for revenue generation.
• The collaboration aims to improve treatment options for pancreatic cancer, a disease with limited effective therapies.
• The agreement includes a perpetual, royalty-free right for ABVC to use and reference any development, regulatory, and market data associated with the Licensed Product in ONCOXs control.

Negatives

• The $1.25 million milestone payment is not guaranteed and depends on OncoX's future fundraising.
• The royalty payments are contingent on the successful commercialization of the product, which is uncertain.
• The agreement is for 50% of the worldwide market, meaning ABVC will not benefit from sales in the other 50%.
• The manufacturing of the finished product is subject to further negotiation between the parties.

Risks

• The success of the collaboration depends on OncoX's ability to successfully develop and commercialize the product.
• There is a risk that the product may not receive regulatory approval or achieve commercial success.
• The agreement is subject to various risks and uncertainties, including those related to manufacturing, financing, and regulatory approvals.
• The company is reliant on third parties for manufacturing and commercialization.
• The company is subject to risks associated with clinical trials and regulatory approvals.

Future Outlook

The collaboration aims to deliver a novel treatment option for pancreatic cancer patients by combining resources, expertise, and innovative approaches. The global pancreatic cancer market is expected to grow significantly, presenting a substantial opportunity for the companies.

Management Comments

• Dr. Uttam Patil, ABVC's CEO, stated that the collaboration represents a significant step forward in developing treatments for pancreatic cancer.
• Wen-Pin Yen, CEO of OncoX, expressed commitment to pushing the boundaries of innovation to improve outcomes for patients.

Industry Context

This announcement aligns with the growing focus on developing new treatments for pancreatic cancer, a disease with a high unmet medical need. The collaboration leverages the expertise of both companies to address this challenge. The global cancer therapeutics market is expected to grow significantly, indicating a strong market opportunity for new treatments.

Comparison to Industry Standards

• The licensing agreement structure, with upfront payments, milestone payments, and royalties, is a common practice in the biopharmaceutical industry.
• The 5% royalty rate is within the typical range for pharmaceutical licensing agreements, although specific rates can vary based on the stage of development and market potential.
• The 20-year license term is standard for pharmaceutical products, providing a reasonable period for commercialization and return on investment.
• The agreement is similar to other licensing deals in the biotech sector, where companies collaborate to develop and commercialize promising drug candidates.
• The global pancreatic cancer market size is estimated to be $2.22 billion in 2022 and is expected to reach $7.91 billion by 2032, which is a significant market opportunity for the companies.

Stakeholder Impact

• Shareholders may benefit from the potential revenue and growth opportunities.
• Employees may have new opportunities related to the development and commercialization of the product.
• Patients may benefit from a new treatment option for pancreatic cancer.
• Suppliers may have new opportunities related to the manufacturing of the product.
• Creditors may benefit from the potential revenue and growth opportunities.

Next Steps

• OncoX will proceed with regulatory filings and commercialization of BLEX 404 in the licensed territory.
• ABVC will provide the product at cost to support clinical development.
• Both companies will continue to collaborate on the development and commercialization of the product.
• Further study and analysis are to be performed for the feasibility from technical and financial perspective before the execution of related manufacturing agreement.

Key Dates

Keywords

Pancreatic Cancer, BLEX 404, Licensing Agreement, OncoX BioPharma, ABVC BioPharma, Rgene Corporation, Maitake Mushroom, Combination Therapy, Royalties, Biopharmaceutical